GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » The Medicines Co (NAS:MDCO) » Definitions » ROE %

The Medicines Co (The Medicines Co) ROE % : -4,881.68% (As of Sep. 2019)


View and export this data going back to 2000. Start your Free Trial

What is The Medicines Co ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. The Medicines Co's annualized net income for the quarter that ended in Sep. 2019 was $-295.98 Mil. The Medicines Co's average Total Stockholders Equity over the quarter that ended in Sep. 2019 was $6.06 Mil. Therefore, The Medicines Co's annualized ROE % for the quarter that ended in Sep. 2019 was -4,881.68%.

The historical rank and industry rank for The Medicines Co's ROE % or its related term are showing as below:

MDCO's ROE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 4.385
* Ranked among companies with meaningful ROE % only.

The Medicines Co ROE % Historical Data

The historical data trend for The Medicines Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Medicines Co ROE % Chart

The Medicines Co Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.55 -42.25 -16.98 -208.82 -9,294.79

The Medicines Co Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -4,881.68

Competitive Comparison of The Medicines Co's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, The Medicines Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Medicines Co's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, The Medicines Co's ROE % distribution charts can be found below:

* The bar in red indicates where The Medicines Co's ROE % falls into.



The Medicines Co ROE % Calculation

The Medicines Co's annualized ROE % for the fiscal year that ended in Dec. 2018 is calculated as

ROE %=Net Income (A: Dec. 2018 )/( (Total Stockholders Equity (A: Dec. 2017 )+Total Stockholders Equity (A: Dec. 2018 ))/ count )
=-123.156/( (24.914+-22.264)/ 2 )
=-123.156/1.325
=-9,294.79 %

The Medicines Co's annualized ROE % for the quarter that ended in Sep. 2019 is calculated as

ROE %=Net Income (Q: Sep. 2019 )/( (Total Stockholders Equity (Q: Jun. 2019 )+Total Stockholders Equity (Q: Sep. 2019 ))/ count )
=-295.976/( (38.129+-26.003)/ 2 )
=-295.976/6.063
=-4,881.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2019) net income data. ROE % is displayed in the 30-year financial page.


The Medicines Co  (NAS:MDCO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2019 )
=Net Income/Total Stockholders Equity
=-295.976/6.063
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-295.976 / 0)*(0 / 926.7715)*(926.7715 / 6.063)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*152.8569
=ROA %*Equity Multiplier
=N/A %*152.8569
=-4,881.68 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2019 )
=Net Income/Total Stockholders Equity
=-295.976/6.063
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-295.976 / -295.936) * (-295.936 / -245.476) * (-245.476 / 0) * (0 / 926.7715) * (926.7715 / 6.063)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0001 * 1.2056 * N/A % * 0 * 152.8569
=-4,881.68 %

Note: The net income data used here is four times the quarterly (Sep. 2019) net income data. The Revenue data used here is four times the quarterly (Sep. 2019) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


The Medicines Co ROE % Related Terms

Thank you for viewing the detailed overview of The Medicines Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


The Medicines Co (The Medicines Co) Business Description

Traded in Other Exchanges
N/A
Address
8 Sylvan Way, Parsippany, NJ, USA, 07054
The Medicines Company is a pharmaceutical firm that provides products to the U.S. hospital market. The company's primary commercial product, Angiomax, is an anticoagulant drug used in conjunction with aspirin for patients undergoing angioplasty. Medicines recently commercialized a new drug, Cleviprex, which is designed to control blood pressure in intensive-care settings.
Executives
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Peter Wijngaard officer: Chief Development Officer 8 SYLVAN WAY, PARSIPPANY NJ 07054
Paris Panayiotopoulos director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Geno J Germano director 5 GIRALDA FARMS, MADISON NJ 07940
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christopher T Cox officer: EVP & Chief Corp. Dev. Officer CADWALADER, WICKERSHAM & TAFT LLP, ONE WORLD FINANCIAL CENTER, NEW YORK NY 10281
Fredric N Eshelman director, officer: Executive Chairman PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Armin M Kessler director
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Hiroaki Shigeta director THE MEDICINES COMPANY, 8 SYLVAN WAY, PARSIPPANY NJ 07054
Stuart A Kingsley officer: President and COO 152 CHESTNUT STREET, WEST NEWTON MA 02465
Robert G. Savage director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Glenn Sblendorio director, officer: President & CFO 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
James E Flynn 10 percent owner, other: Possible Members of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Members of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010